Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II 6-week randomized double-blind trial of BI 1358894 versus quetiapine in major depressive disorder
2019-004264-21Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bi 1358894 in major depressive disorder (MDD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in MADRS total score at Week 6. Started May 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-004264-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004264-21.